CoChat

A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima

Open access
Pisupati, Karthik, Tian, Yuwei, Okbazghi, Solomon, Benet, Alexander, Ackermann, Rose, Ford, Michael, Saveliev, Sergei, Hosfield, Christopher M., Urh, Marjeta, Carlson, Eric, Becker, Christopher, Tolbert, Thomas J., Schwendeman, Steven P., Ruotolo, Brandon T., Schwendeman, Anna · 2017 · Analytical Chemistry
Cited by 75

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

In April 2016, the Food and Drug Administration approved the first biosimilar monoclonal antibody (mAb), Inflectra/Remsima (Celltrion), based off the original product Remicade (infliximab, Janssen). Biosimilars promise significant cost savings for patients, but the unavoidable differences between innovator and copycat biologics raise questions regarding product interchangeability. In this study, Remicade and Remsima were examined by native mass spectrometry, ion mobility, and quantitative peptide mapping. The levels of oxidation, deamidation, and mutation of individual amino acids were remarkably similar. We found different levels of C-terminal truncation, soluble protein aggregates, and glycation that all likely have a limited clinical impact. Importantly, we identified more than 25 glycoforms for each product and observed glycoform population differences, with afucosylated glycans accounting for 19.7% of Remicade and 13.2% of Remsima glycoforms, which translated into a 2-fold reduction in the level of FcγIIIa receptor binding for Remsima. While this difference was acknowledged in Remsima regulatory filings, our glycoform analysis and receptor binding results appear to be somewhat different from the published values, likely because of methodological differences between laboratories and improved glycoform identification by our laboratory using a peptide map-based method. Our mass spectrometry-based analysis provides rapid and robust analytical information vital for biosimilar development. We have demonstrated the utility of our multiple-attribute monitoring workflow using the model mAbs Remicade and Remsima and have provided a template for analysis of future mAb biosimilars.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.analchem.6b04436

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 75

Metadata

Authors
Pisupati, K., Tian, Y., Okbazghi, S., Benet, A., Ackermann, R., Ford, M., Saveliev, S., Hosfield, C. M., Urh, M., Carlson, E., Becker, C., Tolbert, T. J., Schwendeman, S. P., Ruotolo, B. T., & Schwendeman, A.
Venue
Analytical Chemistry
Published
2017-04-17
Volume
89
Issue
9
Pages
4838-4846
ISSN
  • 0003-2700 (ISSN-L)
  • 1520-6882
OpenAlex
W2597473030
Cited by
75
References
2
FWCI
4.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima. https://app.cochat.ai/papers/10.1021/acs.analchem.6b04436
The paper
Pisupati, K., Tian, Y., Okbazghi, S., Benet, A., Ackermann, R., Ford, M., Saveliev, S., Hosfield, C. M., Urh, M., Carlson, E., Becker, C., Tolbert, T. J., Schwendeman, S. P., Ruotolo, B. T., & Schwendeman, A. (2017). A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.6b04436

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.